Lefradafiban

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326949

CAS#: 149503-79-7

Description: Lefradafiban, also known as BIBU-104, is a glycoprotein IIb/IIIa receptor antagonist potentially for the treatment of thrombosis.


Chemical Structure

img
Lefradafiban
CAS# 149503-79-7

Theoretical Analysis

MedKoo Cat#: 326949
Name: Lefradafiban
CAS#: 149503-79-7
Chemical Formula: C23H25N3O6
Exact Mass: 439.17
Molecular Weight: 439.468
Elemental Analysis: C, 62.86; H, 5.73; N, 9.56; O, 21.84

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lefradafiban; BIBU-104; BIBU 104; BIBU104.

IUPAC/Chemical Name: methyl 2-((3S,5S)-5-(((4'-(N-(methoxycarbonyl)carbamimidoyl)-[1,1'-biphenyl]-4-yl)oxy)methyl)-2-oxopyrrolidin-3-yl)acetate

InChi Key: PGCFXITVMNNKON-ROUUACIJSA-N

InChi Code: InChI=1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1

SMILES Code: O=C(OC)C[C@H]1C(N[C@H](COC2=CC=C(C3=CC=C(C(NC(OC)=O)=N)C=C3)C=C2)C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 439.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004 Jan;56(1):43-51. PubMed PMID: 14980000.

2: Doggrell SA. Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding? Drugs Today (Barc). 2001 Aug;37(8):509-531. PubMed PMID: 12743636.

3: Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26. PubMed PMID: 11301411.

4: Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. PubMed PMID: 11250974; PubMed Central PMCID: PMC1729676.

5: McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess. 2000;4(30):1-95. Review. PubMed PMID: 11154975.

6: Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J. 2000 Dec;21(24):2042-55. PubMed PMID: 11102255.

7: Curtin R, Fitzgerald DJ. A cold start for oral glycoprotein IIb/IIIa antagonists. Eur Heart J. 2000 Dec;21(24):1992-4. PubMed PMID: 11102247.

8: Drewe J, Narjes H, Heinzel G, Brickl RS, Rohr A, Beglinger C. Absorption of lefradafiban from different sites of the gastrointestinal tract. Br J Clin Pharmacol. 2000 Jul;50(1):69-72. PubMed PMID: 10886122; PubMed Central PMCID: PMC2014969.

9: Lefradafiban. BIBU 104, BIBU 104XX. Drugs R D. 1999 May;1(5):383-4. PubMed PMID: 10566070.

10: Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost. 1999 Oct;82(4):1307-11. PubMed PMID: 10544919.

11: Ferguson JJ. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation. 1999 Aug 10;100(6):570-5. PubMed PMID: 10441090.

12: Chong PH. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases. Am J Health Syst Pharm. 1998 Nov 15;55(22):2363-86. Review. PubMed PMID: 9825033.

13: Müller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997 Aug 19;96(4):1130-8. PubMed PMID: 9286940.